Medical Doctor Program year 2024 Reported 2023–2024 Source: CMS Open Payments, 2026 publication

Annalisa Gorman

MOHS-Micrographic Surgery Seattle, WA Medical Doctor

NPI 1780765800 CMS profile 126580

1229 Madison St, Suite 1480, Seattle, WA 98104

Open in the dashboard

General payments

$65

2 records reported · program years 2023–2024

Research payments

$0

Paid to them · None reported · program years 2023–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Annalisa Gorman of Seattle, WA is reported in the CMS Open Payments database as having received $65 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 5th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $40 1
2023 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annalisa Gorman
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Annalisa Gorman were reported at $0. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Annalisa Gorman MOHS-Micrographic Surgery median Middle half National median
2019 $0 $316 $106–$785 $163
2020 $0 $162 $68–$412 $114
2021 $0 $243 $87–$654 $132
2022 $0 $300 $102–$887 $149
2023 $25 $364 $125–$1,010 $160
2024 $40 $445 $142–$1,108 $164
2025 $0 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2023–2024
  1. AbbVie, Inc. $40 1 payment
  2. Organogenesis Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2024
  1. Grant $40 1 payment
  2. Food and Beverage $25 1 payment
Products named General payments · program years 2023–2024
  1. Puraply $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

383

Median for Dermatology: 534

Drug cost

$2,497

Median for Dermatology: $67,151

Branded share of claims

14.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 94 $828
Doxycycline Hyclate Generic 105 $778
Mupirocin Generic 51 $377
Cephalexin Generic 65 $352
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $155
Lorazepam Generic 12 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$812,727

Of which drugs: $288

Medicare patients

788

Average age 78

Services billed

2,855

390 women, 398 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 41%
Ischemic heart disease 24%
Atrial fibrillation 22%
Cancer 17%
Osteoporosis 17%
Chronic kidney disease 16%
Diabetes 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 24 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record